Nakai H, Higashi T, Kakuwa T et al (2024) Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol 29:363–371. https://doi.org/10.1007/s10147-024-02473-8

Article  PubMed  Google Scholar 

Konishi I, Abiko K, Hayashi T et al (2022) Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. J Gynecol Oncol 33:e83. https://doi.org/10.3802/jgo.2022.33.e83

Article  PubMed  PubMed Central  Google Scholar 

Yoshihara K, Baba T, Tokunaga H et al (2023) Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 study. Cancer Sci 114:2515–2523. https://doi.org/10.1111/cas.15747

Article  PubMed  PubMed Central  Google Scholar 

Takamatsu S, Yoshihara K, Baba T et al (2023) Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. Br J Cancer 128:1095–1104. https://doi.org/10.1038/s41416-022-02122-9

Article  PubMed  PubMed Central  Google Scholar 

Nakai H, Matsumura N (2022) Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. Int J Clin Oncol 27:1001–1012. https://doi.org/10.1007/s10147-022-02163-3

Article  PubMed  PubMed Central  Google Scholar 

Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. BioMed Res Int. https://doi.org/10.1155/2014/934261

Article  PubMed  PubMed Central  Google Scholar 

Willis SE, Winkler C, Roudier MP et al (2021) Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer 125:1666–1676. https://doi.org/10.1038/s41416-021-01560-1

Article  PubMed  PubMed Central  Google Scholar 

Takaya H, Takamatsu S, Nakai H et al (2025) Homologous recombination deficiency: a reliable biomarker or a misleading indicator? Expert Rev Mol Diagn 25:199–201. https://doi.org/10.1080/14737159.2025.2485212

Article  PubMed  Google Scholar 

Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–92. https://doi.org/10.1056/NEJMoa1105535

Article  PubMed  Google Scholar 

Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164. https://doi.org/10.1056/NEJMoa1611310

Article  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949–1961. https://doi.org/10.1016/S0140-6736(17)32440-6

Article  PubMed  PubMed Central  Google Scholar 

Ledermann JA, Harter P, Gourley C et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17:1579–1589. https://doi.org/10.1016/S1470-2045(16)30376-X

Article  PubMed  Google Scholar 

Matulonis UA, Herrstedt J, Oza A et al (2025) ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety. Gynecol Oncol 195:192–199. https://doi.org/10.1016/j.ygyno.2025.03.018

Article  PubMed  Google Scholar 

Ledermann JA, Oza AM, Lorusso D et al (2025) Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Eur J Cancer 225:115584. https://doi.org/10.1016/j.ejca.2025.115584

Article  PubMed  PubMed Central  Google Scholar 

Friedlander M, Matulonis U, Gourley C et al (2018) Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 119:1075–1085. https://doi.org/10.1038/s41416-018-0271-y

Article  PubMed  PubMed Central  Google Scholar 

O’Malley DM, Oza AM, Lorusso D et al (2022) Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol 167(3):404–413. https://doi.org/10.1016/j.ygyno.2022.08.021

Article  PubMed  PubMed Central  Google Scholar 

Abe M, Hashimoto H, Soejima A et al (2025) Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan. J Gynecol Oncol 36:e47. https://doi.org/10.3802/jgo.2025.36.e47

Article  PubMed  Google Scholar 

Frei E 3rd (1985) Curative cancer chemotherapy. Cancer Res 45(12 Pt 1):6523–6537

PubMed  Google Scholar 

Cline MS, Liao RG, Parsons MT et al (2018) BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet 14(12):e1007752. https://doi.org/10.1371/journal.pgen.1007752

Article  PubMed  PubMed Central  Google Scholar 

Takashima T, Taniyama D, Sakamoto N et al (2021) Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. Br J Cancer 125:65–77. https://doi.org/10.1038/s41416-021-01364-3

Article  PubMed  PubMed Central  Google Scholar 

Takashima T, Sakamoto N, Murai J et al (2021) Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. Virchows Arch 478:569–579. https://doi.org/10.1007/s00428-020-02840-6

Article  PubMed  Google Scholar 

Takamatsu S, Hillman RT, Yoshihara K et al (2024) Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study. Br J Cancer 131:1340–1349. https://doi.org/10.1038/s41416-024-02837-x

Article  PubMed  PubMed Central  Google Scholar 

Oda K, Aoki D, Tsuda H et al (2023) Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer. Cancer Sci 114:271–280. https://doi.org/10.1111/cas.15518

Article  PubMed  Google Scholar 

Oza AM, Tinker AV, Oaknin A et al (2017) Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 147:267–275. https://doi.org/10.1016/j.ygyno.2017.08.022

Article  PubMed  Google Scholar 

Fong PC, Yap TA, Boss DS et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–9. https://doi.org/10.1200/JCO.2009.26.9589

Article  PubMed  Google Scholar 

Moore KN, Secord AA, Geller MA et al (2019) Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:636–648. https://doi.org/10.1016/S1470-2045(19)30029-4

Article  PubMed  Google Scholar 

Swisher EM, Kwan TT, Oza AM et al (2021) Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun 12:2487. https://doi.org/10.1038/s41467-021-22582-6

Article  PubMed  PubMed Central  Google Scholar 

Nakai H, Matsumura N (2023) Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics. Expert Opin Pharmacother 24:2161–2173. https://doi.org/10.1080/14656566.2023.2295393

Article  PubMed  Google Scholar 

Nakai H, Matsumura N (2022) The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol 27:1120–1126. https://doi.org/10.1007/s10147-022-02169-x

Article